Oestrogen receptors, nodes and stage as predictors of post-recurrence survival in 457 breast cancer patients. by Shek, L. L. et al.
Br. J. Cancer (1987), 56, 825-829
.j The Macmillan Press Ltd., 1987
Oestrogen receptors, nodes and stage as predictors of post-recurrence
survival in 457 breast cancer patients
I
L.L.M. Shekl, W. Godolphin' & J.J. Spinelli2
'Department ofPathology, Vancouver General Hospital and the University ofBritish Columbia and 2Division ofEpidemiology,
Biometry and Occupational Oncology, Cancer Control Agency ofBritish Columbia, Vancouver, B.C., Canada V5Z 1M9.
Summary The relationship to survival after first recurrence of oestrogen receptor (ER), nodal status and
TNM stage at diagnosis, and treatment for advanced disease was studied in 457 females whose primary breast
cancer was diagnosed in 1975 to 1981. Receptor concentration was the most important predictor of post-
recurrence survival, with some additional information conveyed by nodal status. ER predicted survival after
recurrence independently of nodal status, clinical stage or mode of therapy. Response to endocrine therapy is
only a facet of the generally favourable prognosis of ER positive patients, rather than the sole explanation.
The utility of oestrogen receptor (ER) measurement for
predicting breast cancer survival has been extensively
studied. The general consensus is that overall survival time,
from initial diagnosis or primary treatment, is increased with
tumours rated ER positive (ER+) by various definitions.
The association between ER status and recurrence-free
survival (RFS) is less clear, and is in fact confused by
disparate subset analyses in different studies. It is uncertain
if RFS is significantly different between ER + and ER
negative (ER-) patients when they are node-negative and
postmenopausal (Crowe et al., 1982), when nodes are
involved (Caldarola et al., 1986) or when patients are
premenopausal regardless of node involvement (Samaan et
al., 1981). These subset inconsistencies and differences in
RFS observed in early follow-up tend to disappear in the
long-term (Howat et al., 1985; Raemaekers et al., 1985; Saez
et al., 1983). This unclear role of ER in predicting RFS
impacts on the question of whether overall survival is more
favourable in ER+ than ER- tumours because of longer
RFS, or longer post-recurrence survival (PRS), or both.
The association of ER with PRS has been relatively less
scrutinized. In a study based on 137 patients with recurrence,
Howell et al. (1984) reported that ER+ patients showed a
significantly longer survival after relapse than ER- patients.
However, this effect was related to response to endocrine
therapy. PRS was the same in ER+ nonresponders (n=19)
as ER- nonresponders (n= 18) but both groups had
significantly worse PRS than ER + responders (n =24).
Howat et al. (1985) in a relatively small study (n=51) found
that PRS was better in ER+ patients and suggested this to
be predominantly a result of better response to endocrine
therapy given for recurrence.
We also found a significant association of higher ER
concentration and increased PRS among a subset (n=59)
which had received endocrine therapy (Godolphin et al.,
1981). The patients of that previous study have now been
followed up to ten years. Additional patients whose primary
tumours were diagnosed and analysed for ER have been
followed for a minimum of four years by the same referral
centre.
The present study, with increased sample size and time of
follow-up, was undertaken to test the hypothesis that ER is
associated with PRS more generally and not simply through
response to endocrine therapy. In addition nodal status and
TNM stage were examined. These are both strong predictors
of RFS but do not have a well established prognostic role
for PRS.
Materials and methods
Patients
PRS analysis was performed on 457 patients, a subset of a
large study group of 1,184 female patients with primary
breast carcinoma, who were referred to the Cancer Control
Agency of British Columbia (CCABC) in Vancouver
between 1975 and 1981, and who met the inclusion criteria:
satisfactory ER determination on the primary tumour;
known dates of diagnosis and recurrence; no previous,
concomitant or later developed malignancy regardless of site
(including bilateral breast cancer) except non-melanoma
squamous cell and basal cell carcinomas of the skin.
Postoperative clinical follow-up conformed with a definite
schedule. Patients who were surgically treated, with or
without postoperative radiation, received complete physical
examination one month after radiation therapy (at CCABC),
every three months until the second year (alternating
between CCABC clinic and referring physician), every six
months from third to fifth year (by referring physician) and
once a year thereafter. Chest X-ray and mammogram of the
opposite breast were repeated annually. Patients who
received adjuvant chemotherapy underwent detailed physical
examination at the start of each course of therapy. While
patients were on an adjuvant regimen blood count and liver
function tests were repeated at each visit; chest X-ray and
carcinoembryonic antigen were assessed every three months.
Bone scan and mammogram of the opposite breast were
performed annually or sooner if indicated. Results of follow-
up by referring physicians were reported on a standardized
form which was returned to the CCABC. If recurrent disease
was suspected or evident, patients were referred back to the
CCABC for evaluation and therapy planning. Histo-
pathologic diagnoses of malignancy consistent with the
primary tumour or evidence of metastatic disease on
radiologic scans were used to confirm recurrent disease.
Recurrent disease was treated with various modalities,
depending on the site of disease, hormone receptor status,
and menopausal status. Treatment for patients with loco-
regional recurrence was radiation therapy to chest wall and
lymph node drainage areas, which would be preceded by
surgical excision if disease was confined to a local area. The
initial treatment for patients with no or low ER, regardless
of menopausal status, was cytotoxic chemotherapy (e.g.,
adriamycin and cyclophosphamide or cyclophosphamide,
methotrexate and 5-fluorouracil). Endocrine therapy was
given to both premenopausal and postmenopausal ER+
patients who did not demonstrate a short disease-free
interval. Ovarian ablation (surgical oophorectomy or ovarian
irradiation) was performed on premenopausal ER + patients.
The predominant type of endocrine therapy for post-
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menopausal ER+ patients was tamoxifen. Radiation therapy
was also given with systemic therapy for symptomatic
palliation.
ER analysis
Tumour biopsies or mastectomy specimens of all patients
eligible for the study were analysed for ER by procedures
described in detail elsewhere (Elwood & Godolphin, 1980;
Jacobson, 1981). Tumours were frozen, transported and
stored in liquid nitrogen, then trimmed to remove fatty,
fibrotic and necrotic material. All procedures including
trimming were maintained at <4°C. Tumours were
pulverized with a Braun Micro-dismembrator, homogenized
in buffer and centrifuged at 39,000g for 15min to isolate
cell cytosol which was incubated with 3H-
oestradiol +competitor. Unbound and loosely bound
hormone was removed with dextran-coated charcoal and
remaining bound 3H-oestradiol measured by liquid
scintillation counting. Receptor concentration was
quantitated by Scatchard or Woolf plot. Oestrogen receptor
concentration was expressed as femtomoles of bound
oestradiol per mg of cytosol protein corrected for variable
serum protein in the cytosol preparation. This is in
accordance with the recommendation of the EORTC Breast
Cancer Cooperative Group (1973). A correction factor of
1.67, based on the average ratio of total protein and albumin
in normal sera, was applied to the albumin concentration
determined by radial immunodiffusion. The estimated tissue
cytosol protein was calculated as the difference between
measured total protein and the estimated serum protein
(Jacobson, 1980). All ER analyses were performed in the
same laboratory, under the supervision of WG, where the
technique has remained essentially unchanged throughout
the study period. In-house quality control measures
(Godolphin & Jacobson, 1980) and participation in a
national quality control programme (Ryan et al., 1985) have
indicated a reliable and reproducible assay over the years of
data collection for this study.
Staging and nodal status
Clinical TNM stage according to the Union Internationale
contre le Cancer criteria was assigned to patients with
complete information on size of lump with or without
fixation to underlying pectoralis muscle or chest wall,
palpability of axillary lymph nodes, and presence or absence
of distant spread as verified by metastatic work-up.
The number of axillary nodal metastases was taken from
the original pathology report and categorized as NO, N1-3
and N4+.
Statistical analyses
Survival curves were estimated by the product limit
method (Kaplan & Meier, 1958). Mantel-Cox tests were
used to test for differences in the survival curves defined by
different covariates (Kalbfleisch & Prentice, 1980).
Programme P: 1L of BMDP Statistical Software (Dixon,
1983) was used. The Cox proportional hazards model (Cox,
1972) was used to test the influence of therapy group, nodal
status and TNM stage on the apparent effect of ER
concentration.
Overall survival refers to the time elapsed from date of
diagnosis to date of breast cancer specific death taken from
the death certificate or autopsy report. Recurrence was
defined as the first confirmed disease relapse, which might
have been locoregional (chest wall, ipsilateral regional nodes,
ipsilateral breast of patients not having had a mastectomy)
or distant dissemination (bone, visceral organs, brain). Post-
recurrence survival (PRS) was the time from a recurrence to
the date of breast cancer specific death. The date of last
follow-up was used as the endpoint in lieu of the date of
death for patients alive at the end of the study period.
Deaths due to other causes were treated as censored data
(12% of deaths), as were patients who were alive with
evidence of disease. Patients presenting with TNM IV or
persistent disease were excluded from PRS analysis. The
number of patients per analysis differed according to the
completeness of data on the individual variables.
Results
Four hundred and fifty-seven patients had an objectively
determined recurrence. The relationship between ER con-
centration in the primary tumour and prolongation of PRS
was highly significant (Figure 1). The median survival of 46
months in the ER.160 group was much more favourable
than in the other three (ER=10-159: 27 months' ER=2-9:
16 months; ER< 1: 12 months).
The influence of other prognostic factors on this
relationship was evaluated by the Cox proportional hazards
model. ER concentration, therapy, number of involved
axillary nodes and TNM stage were significant univariate
predictors ofPRS (Table II). The PRS curves as a function of
pathological nodal status ascertained at the time of primary
diagnosis are shown in Figure 2. The difference between the
post-recurrent survival of the three nodal groups was highly
significant (P=0.0001). A significant difference in PRS
occurred between clinical TNM stage groups (Figure 3).
The importance of a single factor in PRS prediction was
assessed in relation to the other factors by stepwise analysis.
The first variable selected to be an independent prognostic
factor was ER, followed by nodal status (Table II). An
insignificant interaction term was found (P>0.2) for ER
concentration and type of therapy, suggesting that
quantitative ER was predictive of PRS regardless of therapy.
This is supported by a significant relationship between ER
and PRS in the group of 141 patients who were not given
any endocrine therapy (P=0.001). Quantitative ER retained
its significance in association with PRS after stratification by
TNM stage and nodal status, although there was a
suggestion that this association was not present in the N4+
subset (data not shown). However, results from interaction
tests of ER with nodal status, and ER with TNM stage
showed that the effect of ER on PRS was not dependent on
the other two factors (Table II).
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Figure 1 Post-recurrence survival: division by ER concentration
(fmolmg-1 cytosol protein) in primary tumour. The number at
risk in each group were: ER. 160, 84; ER= 10-159, 206;
ER=2-9, 110; ER. 1, 49. Survival curves discontinued when
fewer than 10 patients under follow-up; P<0.0001.POST RECURRENCE SURVIVAL WITH BREAST CANCER 827
Table I Distribution of patients by characteristic; the number of patients in each category is given. Median
follow-up after recurrence= 18 months
Age at diagnosis, years <45
89
45-54
108
55-64
118
>64
132
Menopausal status
ER conc. in primary
fmolmg-1 cytosol protein
ER status
TNM stage
Axillary node involvement
Primary treatment
Therapy
Outcome
Premenopausal
126
Postmenopausal
315
Unknown
16
< 1 2-9 10-159 _160 Unknown
49 110 206 84 8
ER+ ER-
284 165
Unknown
8
I II III Indeterminate
99 252 87 19
NO N1-3
101 133
Surgery Surgery+
only radiation
158 253
Cytotoxic
Endocrine chemo-
149 57
Dead of
breast
Alive cancer
131 287
N4+
157
Biopsy
only
11
Unknown
43
Biopsy+
radiation
33
Unknown
2
Sequentiala None
167 84
Dead of
other
causes
39
Lost to
follow-up
0
aBoth endocrine and cytotoxic chemotherapies given, sequentially.
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Figure 2 Post-recurrence survival: division by number of
axillary nodes involved at the time of primary diagnosis. The
number at risk in each group were: NO, 100; N1-3, 133; N4+,
154. Four patients with known nodal status and ER
concentration had PRS<1 month. Survival curves discontinued
when fewer than 10 patients under follow-up; P=0.0001.
Discussion
Survival after the first relapse is associated with higher ER
in the primary tumour. Others have found a significant
correlation between ER status (ER+ and ER-) and time
from recurrence to death (Paterson et al., 1982; Lionetto et
al., 1986), and we extend this to show that greater
discrimination is afforded by observing not only ER status
but ER concentration ranges. The subset with primary
ER>160 consistently showed superior PRS when the 457
patients were analysed as a group, and after stratification by
nodal status and TNM stage.
0 5
Time (years)
Figure 3 Post-recurrence survival: division by clinical TNM
stage at the time of primary diagnosis. The number at risk in
each group were: TNM I, 98; TNMII, 250; TNMIII, 86. Four
patients with known TNM stage and ER concentration had
PRS <1 month. Survival curves discontinued when fewer than 10
patients under follow-up; P=0.01.
The results from the Cox proportional hazards analysis
suggest that quantitative ER is the most important factor to
identify patients at high- risk of early death after disease
recurrence. While pathologic nodal status contributes to
prediction of PRS, TNM staging of the primary tumour is
irrelevant once the other two factors are known. The amount
of ER present in the primary tumour represents an
important biological characteristic that influences PRS over
and above the effects of therapy, nodal status and TNM
stage, since the first-order interactions of ER and these
factors produced no statistically significant effect on PRS.
That higher ER in the primary tumour associates with
100
26
am
I An828 L.L.M. SHEK et al.
Table II Stepwise regression analysis by the Cox proportional hazards model of 390
cases with complete information on all studied variables
Likelihood
Step Variable ratio X2 df P
I ER concentration 32.3 3 <0.0001
Pathological nodal status (Nodes) 20.0 2 <0.0001
Clinical stage (TNM) 6.7 2 0.035
First-line therapy (Therapy) 10.9 3 0.012
2 ER+Nodes 21.2 2 <0.0001
ER+TNM 7.1 2 0.029
ER+Therapy 6.3 3 0.10
3 ER+Nodes+TNM 4.3 2 0.12
ER+Nodes+Therapy 5.2 3 0.16
ER+Nodes+Therapy+(ER xTherapy) 11.8 9 0.22
ER+Nodes+(ER x Nodes) 5.4 6 0.49
ER+Nodes+TNM+(ER xTNM) 9.6 6 0.14
more favourable PRS may relate to the intrinsic biologic
behaviour of the cancer. Indirect measurements of tumour
growth rate, in terms of thymidine labelling index (Silvestrini
et al., 1979) or mean proportion of cells engaged in DNA
synthesis (McDivitt et al., 1986), are inversely correlated
with ER. Thus, it has been suggested that ER reflects more
precisely the timing of a recurrence, if it is to occur, rather
than the metastatic potential (McGuire et al., 1986). We
have previously found a significant association between ER
concentration and recurrence-free survival (Godolphin et al.,
1981).
The degree of tumour differentiation is a strong correlate
of tumour ER (Fisher et al., 1981; Alanko et al., 1984) and
is another indicator of tumour aggressiveness. ER content
has also been found to relate to the site of initial metastases
(Campbell et al., 1981; Williams et al., 1987). It is likely that
well differentiated ER+ tumours will maintain a low growth
rate even after the establishment of a metastasis, which is
more often in bone, and tend to have a less aggressive course
than metastases to visceral organs (Coleman & Rubens,
1987). Response by ER+ tumours to endocrine therapy may
vary according to site: recalcification of bone may be less
frequent than soft tissue tumour regression and appears to
depend on the availability of specific matrix requirements
(Stoll, 1985).
In contrast, ER- tumours that tend to be poorly differ-
entiated may have a faster growth rate. This would increase
the pace of acquisition of genetic variability and instability,
leading to emergence of subclones with greater growth
autonomy or malignancy (Nowell, 1976). This behaviour
may be maintained even after recurrence but be arrested by
cytotoxic chemotherapy; response to endocrine therapy by
the hormone resistant cells is unlikely. Therefore, the
advantage in survival after recurrence seen among patients
with higher ER relies more on the biologic interplay between
host and tumour than on response to specific endocrine
therapy.
The finding that nodal status predicts PRS contradicts
several reports (Paterson et al., 1982; Howat et al., 1985;
Williams et al., 1986). However, Lionetto et al. (1986)
reported a significantly shorter survival after relapse in
patients with axillary node metastases at presentation. A
multivariate analysis by Clark et al. (1985) of predictors of
PRS also showed the importance of axillary lymph node
status at primary diagnosis. Perhaps others, e.g., Howat et
al., (1985), who categorized nodal involvement in the manner
we did, have not detected a difference in PRS according to
nodal status because of small sample size and staging based
on anatomic involvement rather than extent (number of
positive nodes) of involvement (Williams et al., 1986).
We suggest that metastatic involvement of axillary nodes
at the time of primary treatment is another reflection of
tumour aggressiveness. The presence of positive nodes
signals the successful evasion of host immune and
nonimmune defences in the regional lymph nodes (Fisher,
1984; Fidler, 1984). A conducive environment may be
furnished by the host which facilitates the expression of
specific tumour cell properties that permit dislodgment from
the primary site, such as changes in cell surface chemistry
associated with loss of cell adhesiveness (Kim, 1985), and
enhanced tumour invasiveness by increased tumour cell
motility and production of proteolytic enzymes such as
collagenases specifically active against basement membrane
(Liotta, 1984).
The present study demonstrates the importance of ER to
post-recurrence survival. The prognostic role of ER is further
enhanced by stratification into concentration ranges. Further-
more, improved response to endocrine therapy associated
with higher ER is not the only reason for prolonged
PRS, since survival after disease recurrence is significantly
prolonged with higher ER even in patients not given
endocrine therapy. Thus, the effect of primary ER on post-
recurrent survival appears not to depend on the mode of
systemic therapy.
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